Features of Psychotic Symptoms in Methamphetamine Use Disorder Patients and Ketamine Use Disorder Patients: A Cross-Sectional Study.
Central nervous system-related safety and tolerability of add-on ketamine to standard of care treatment in treatment-resistant psychotic depression in patients with major depressive disorder and bipolar disorder.
Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation.
McIntyre RS, Rosenblat JD, Nemeroff CB, Sanacora G, Murrough JW, Berk M, Brietzke E, Dodd S, Gorwood P, Ho R, Iosifescu DV, Lopez Jaramillo C, Kasper S, Kratiuk K, Lee JG, Lee Y, Lui LMW, Mansur RB, Papakostas GI, Subramaniapillai M, Thase M, Vieta E, Young AH, Zarate CA Jr, Stahl S.
Am J Psychiatry. 2021 May 1;178(5):383-399. doi: 10.1176/appi.ajp.2020.20081251. Epub 2021 Mar 17.
Lithium treatment of Bipolar disorder in adults: A systematic review of randomized trials and meta-analyses.
Fountoulakis KN, Tohen M, Zarate CA Jr.
Eur Neuropsychopharmacol. 2022 Jan;54:100-115. doi: 10.1016/j.euroneuro.2021.10.003.
Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression.
Anand A, Mathew SJ, Sanacora G, Murrough JW, Goes FS, Altinay M, Aloysi AS, Asghar-Ali AA, Barnett BS, Chang LC, Collins KA, Costi S, Iqbal S, Jha MK, Krishnan K, Malone DA, Nikayin S, Nissen SE, Ostroff RB, Reti IM, Wilkinson ST, Wolski K, Hu B.
N Engl J Med. 2023 Jun 22;388(25):2315-2325. doi: 10.1056/NEJMoa2302399. Epub 2023 May 24.
Ketamine for the acute treatment of severe suicidal ideation: double blind, randomised placebo controlled trial.
Abbar M, Demattei C, El-Hage W, Llorca PM, Samalin L, Demaricourt P, Gaillard R, Courtet P, Vaiva G, Gorwood P, Fabbro P, Jollant F.
BMJ. 2022 Feb 2;376:e067194. doi: 10.1136/bmj-2021-067194.
Striatal dopamine mediates hallucination-like perception in mice.
Schmack K, Bosc M, Ott T, Sturgill JF, Kepecs A.
Science. 2021 Apr 2;372(6537):eabf4740. doi: 10.1126/science.abf4740.
Dopamine and glutamate in schizophrenia: biology, symptoms and treatment.
McCutcheon RA, Krystal JH, Howes OD.
World Psychiatry. 2020 Feb;19(1):15-33. doi: 10.1002/wps.20693.
Bipolar depression: a major unsolved challenge.
Baldessarini RJ, Vázquez GH, Tondo L.
Int J Bipolar Disord. 2020 Jan 6;8(1):1. doi: 10.1186/s40345-019-0160-1.
An evidence-based approach to psychopharmacology for posttraumatic stress disorder (PTSD) - 2022 update.
Bajor LA, Balsara C, Osser DN.
Psychiatry Res. 2022 Nov;317:114840. doi: 10.1016/j.psychres.2022.114840. Epub 2022 Sep 9.
Racemic Ketamine as an Alternative to Electroconvulsive Therapy for Unipolar Depression: A Randomized, Open-Label, Non-Inferiority Trial (KetECT).
Ekstrand J, Fattah C, Persson M, Cheng T, Nordanskog P, Åkeson J, Tingström A, Lindström MB, Nordenskjöld A, Movahed Rad P.
Int J Neuropsychopharmacol. 2022 May 27;25(5):339-349. doi: 10.1093/ijnp/pyab088.
Efficacy and Tolerability of Combination Treatments for Major Depression: Antidepressants plus Second-Generation Antipsychotics vs. Esketamine vs. Lithium.
Vázquez GH, Bahji A, Undurraga J, Tondo L, Baldessarini RJ.
J Psychopharmacol. 2021 Aug;35(8):890-900. doi: 10.1177/02698811211013579. Epub 2021 Jul 9.
